TrialThe Journal of infectious diseases2018

Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study.

Andreas Ronit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.